Will Merck be next to join Big Pharma’s asset-sale parade?

Tracy Staton Novartis and Pfizer are in the process of spinning off units. Abbott Laboratories set its pharma business free at the beginning of this year. Why wouldn't Merck decide ...

Merck whacking 500 at West Point, PA, plant

Eric Palmer For West Point, PA, Merck giveth and Merck taketh away. In the midst of significant downsizing, right now Merck is taking away 500 jobs from the extensive facility there. FiercePharma ...

Merck sales slump again, but cost cuts keep earnings coming

Tracy Staton On the Big Pharma scorecard, Merck remains on a downward slide. Yes, third-quarter earnings beat estimates, but expectations were low, and it was cost-cutting that delivered ...

UPDATED: The ax drops at troubled Merck as big restructuring gets underway

John Carroll The pink slips are starting to fly at Merck R&D. The rumor mill was running full tilt on Monday morning, with comments flowing across Twitter that planned layoffs are ...

New study raises new questions about Merck cholesterol drug

Tracy Staton A new study finds that the drug lingers in the bodies of patients long after they've stopped using it, sometimes even for years. FiercePharma News

Merck Serono’s new HQ taps open-office style to encourage innovation

Tracy Staton The redesigned buildings on Merck KGaA's campus feature the sort of flexible work stations and open-office arrangements recently adopted by GlaxoSmithKline in Philadelphia ...

Merck puts Whitehouse Station HQ on the block

Tracy Staton Merck's global headquarters is wearing a "For Sale" sign. The company said last year that it would pack up and leave Whitehouse Station, NJ, in a money-saving ...

Merck KGaA eyes KRAS-gene focus to boost Erbitux sales

Carly Helfand In an interview with Reuters, Belén Garijo, head of the company's pharma unit Merck Serono, outlined a strategy for Erbitux centered on the KRAS mutation-free ...

Ray of hope in Merck cost-cutting gloom: New cancer-immunotherapy data

Tracy Staton While headlines focused on Merck's 8,500-job, $ 2.5 billion restructuring yesterday, the pharma giant quietly posted promising early-stage data on what has become ...

Merck KGaA overhauls pharma management to boost growth

Tracy Staton Merck KGaA is rejigging its pharmaceuticals management, promoting pharma chief Stefan Oschmann to a new job overseeing prescription and consumer drugs, biosimilars and ...

Merck KGaA Shares More Management Changes

mia.burns Merck KGaA Announces Further Management Changes to Drive Pharmaceutical Business Growth •Stefan Oschmann to focus on role as Head of Pharmaceuticals in charge of the biopharmaceutical ...

Merck gives up on unsuccessful Januvia combo drug Juvisync

Tracy Staton As it announced cuts to its full-year sales forecast in July, Merck was able to point to growth in sales of Januvia and its offshoots, if only in the low-single-digit range. FiercePharma ...
Page 5 of 11« First...34567...10...Last »
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS